Manish Saran, MD
Child & Adolescent Psychiatry · Shreveport, LANPI 1821208224
Payments from drug & device makers
Across 707 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- Sunovion Pharmaceuticals Inc.$1K
- Neurocrine Biosciences, Inc.$964
- Lundbeck LLC$806
- Teva Pharmaceuticals USA, Inc.$740
- Otsuka America Pharmaceutical, Inc.$690
- plus $5K from 22 others
What the payments were for
- Food & beverage$11,006100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 86 | $1,604 |
| Sunovion Pharmaceuticals Inc. | 113 | $1,122 |
| Neurocrine Biosciences, Inc. | 61 | $964 |
| Lundbeck LLC | 52 | $806 |
| Teva Pharmaceuticals USA, Inc. | 47 | $740 |
| Otsuka America Pharmaceutical, Inc. | 42 | $690 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $665 |
| AbbVie(2 entities) | 63 | $654 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 40 | $627 |
| Corium, LLC | 30 | $590 |
| Johnson & Johnson | 25 | $512 |
| Supernus Pharmaceuticals, Inc. | 21 | $437 |
| Vanda Pharmaceuticals Inc. | 16 | $265 |
| Collegium Pharmaceutical, Inc. | 10 | $186 |
| E.r. Squibb & Sons, L.L.C. | 9 | $165 |
| Ironshore Pharmaceuticals Inc. | 8 | $152 |
| Tris Pharma Inc | 9 | $147 |
| Shire North American Group Inc | 12 | $139 |
| ZOLL Respicardia, Inc. | 1 | $132 |
| Axsome Therapeutics, Inc. | 5 | $103 |
| Sage Therapeutics, LLC | 4 | $73 |
| Idorsia Pharmaceuticals US Inc | 4 | $67 |
| Vertical Pharmaceuticals, LLC | 3 | $61 |
| Bausch Health US, LLC | 2 | $32 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Indivior Inc. | 1 | $18 |
| Eisai Inc. | 1 | $15 |
| Neos Therapeutics, LP | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,473
- remede System$132
How this compares
$11,009 in reported general payments places this provider in the 95th percentile of 70 child & adolescent psychiatry providers in Louisiana.
See all child & adolescent psychiatry providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,652 |
| Ziprasidone Hcl | 16 | $688 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 23 | $166 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Shreveport
- McLeod GwynetteShreveport$168K
- Katherine SmithShreveport$6K
- Swathi ParvataneniShreveport$4K
- Sadaf JavaidShreveport$4K
- Keerthiga RaveendranShreveport$3K
- Hannah ScottShreveport$162
- John WagnerShreveport$153
- Caroline CampionNew Orleans$774K
- Jason WuttkeNew Orleans$11K
- Nicholas LavinLafayette$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.